Background
Colorectal cancer (CRC), is the third most common cancer in the United States, and in 2018 there were an estimated 140,250 new cases resulting in 50,630 associated deaths [1] . CRC is the third leading cause of cancer mortality in both men and women [2] . The incidence of CRC has been declining during the past four decades, mainly due to the reduced risk factors and the use of colonoscopic screening [2] . In patients who have been diagnosed with CRC, the survival and prognosis have improved annually, partly due to the development of improved surgical management and improved systemic chemotherapy regimens [3] . The survival outcome for patients with a diagnosis of CRC has been associated with clinical and histopathological factors, including the tumor site, tumor type, histologic grade, the American Joint Committee on Cancer (AJCC) stage, tumor node metastasis (TNM) status, and a comprehensive treatment strategy [4] .
Recently, clinicians have become increasingly aware of the impact of sociodemographic factors, especially the insurance status, on the diagnosis, treatment, and prognosis of patients with cancer. Previous studies have shown that patients with hepatocellular carcinoma and breast cancer who were on Medicaid or who were uninsured patients tended to have a more advanced stage at diagnosis and were more likely to refuse treatment after diagnosis [5, 6] . Also, insured patients with prostate cancer have been shown to have improved prognosis when compared to patients with Medicaid and uninsured individuals [7] . However, there have been few previous studies on how insurance status impacts the stage at diagnosis, the definitive treatment, and the survival for patients with CRC, using population-based analysis [8] .
This study aimed to use data from the Surveillance, Epidemiology, and End Results (SEER) program [9] to identify all patients with CRC who had specific insurance details and to analyze the effects of the stage at diagnosis, definitive treatment, and survival outcome, with insurance status.
Material and Methods
Search strategy for the Surveillance, Epidemiology, and End Results (SEER) database
The Surveillance, Epidemiology, and End Results (SEER) database is a publicly available program composed of 18 cancer registries and covers approximately 30% of the population in the United States with a typical distribution [10] . The data in the SEER database is de-identified to ensure patient confidentiality. The SEER database is considered to be representative of the entire US population, and includes patient demographic information and data from patient clinical records and followup data of survival. SEER is updated annually by the National Center for Health Statistics.
Permission was obtained to use the SEER database in November 2016 (Authorization number by Author QZT: 12738-Nov.2016). All the patient data were obtained through the SEER*Stat software version 8.3.5 (released on March 6, 2018) (https://seer.cancer.gov/seerstat/), including demographic, clinical and follow-up information. Detailed information of the patients with CRC diagnosed between 2007 and 2009 from the SEER-18 was performed with SEER*Stat software. This study complied with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Approval for this study was waived by the local ethics committee, and no informed consents were needed.
Inclusion criteria for patients with colorectal cancer (CRC) from the SEER database
All patients with colorectal cancer (CRC) were identified during 2007 and 2009 for analysis. The following study inclusion criteria were used: patients were included who were diagnosed with primary CRC, according to the Anatomic International Classification of Diseases for Oncology, Third Edition [ICD-O-3], codes C18.0, C18.1, C18.2, C18.3, C18.4, C18.5, C18.6, C18.7, C18.8, C18.9, C19.9, C20.9); patients were diagnosed between 2007 and 2009, because insurance status was missing in the database for patients diagnosed before 2007, and patients diagnosed after 2009 did not meet the 5-year follow-up period; patients included in the analysis were aged older than 18 years and younger than 85 years at diagnosis; patients were limited to adenocarcinoma (histologic ICD-O-3 codes: 8140, 8210, 8261, 8263, 8481), mucinous adenocarcinoma (histologic ICD-O-3 code: 8480), and signet ring cell carcinoma (histologic ICD-O-3 code: 8490).
The following study exclusion criteria were used: patients with unknown demographic information on gender, age at diagnosis, race, marital status, household income, college completion and rural/metropolitan location; patients with unknown clinical information including histologic grade, and AJCC TNM stage; patients with no information on definitive surgery or radiotherapy; patients with multiple primary tumors; patients with unknown cause of death or unknown survival time; patients with a survival time £1 month; autopsy or death certificate only. 
Data on CRC from the SEER database
Cancer site was classified as the left colon (splenic flexure, descending colon, sigmoid colon), the right colon (cecum, ascending colon, hepatic flexure, transverse colon), and rectosigmoid or the rectum (rectum, rectosigmoid junction). Histologic grade was classified as grade I, II, III, and IV. AJCC TNM stage was classified as stage I, II, III and IV. AJCC T status was classified as T1, T2, T3, and T4. AJCC N status was classified as N0, N1, N2, and N3. AJCC M status was classified as M0 and M1. SEER stage was classified as localized, regional and distant. Surgical treatment and radiotherapy were all defined as having received therapy or not. Chemotherapy was classified as having received chemotherapy or not/unknown. Definitive treatment was defined as receiving definitive surgery, radiotherapy or chemotherapy. Causes of death were classified as tumor cause-specific death (TCSD) and other causespecific death (OCSD).
Statistical analysis
The demographic, clinical, and pathologic features analyzed were summarized by descriptive statistical analysis. Continuous variables with normal distribution were described as the mean ± standard deviation (SD), continuous variables with skewed distribution were described as medians, first quartiles, and third quartiles, and categorical variables were described as frequencies and percentages. For categorical variables, Pearson's chi-squared (c 2 ) test and Fisher's exact tests were used to determine statistical significance. Multinomial logistic regression models were used to detect associations between insurance status and multifactor disease stage at diagnosis by R package of MASS, with the greater the odds ratio (OR) values, the more advanced the cancer stage. Binomial logistic regression models were used to detect associations between insurance status and definitive treatment, with the greater the OR values, the greater the possibility of receiving definitive treatment.
Bar plots were drawn by R package of ggplot2. For tumor causespecific survival (TCSS), deaths caused by CRC were considered as events. Kaplan-Meier analysis and the multivariate Cox proportional hazard model were selected to distinguish independent risk factors by the R package of KMsurv and survival. When displaying Kaplan-Meier curves based on raw data by the survminer R package, due to disequilibrium among different types of insurance, the curves were reproduced after propensity score matching (PSM) by R packages of MatchIt. In the competing risk analysis, OCSD was regarded as the competing event of TCSD. The Fine and Gray proportional sub-distribution hazard model was chosen to predict TCSD by R package cmprsk and riskRegression [11, 12] . All analysis was performed using R statistical software version 3.3.1 (released June 2016) (www.r-project.org). All P-values were two-sided and P<0.05 was considered significant.
Results
Baseline characteristics of patients with colorectal cancer (CRC) from the Surveillance, Epidemiology, and End Results (SEER) database
As shown in Figure 1 
Cancer stage at diagnosis
As shown in Figure 2 , insured patients were more likely to have an earlier SEER stage at diagnosis when compared with Medicaid or uninsured patients. However, uninsured patients had the lowest proportion of SEER localized stage, as well as the highest proportion of SEER distant stage. Univariate analysis, shown in Table 1 showed the findings of the impact of insurance status on SEER stage stratified by age group, race, or cancer site, which showed that insured patients had an earlier stage at diagnosis. Table 3 showed the association between insurance status and AJCC stage, T status, N status and M status stratified by cancer site after changing the response variables in the multivariate logistic models. Finally, insured patients were found to be significantly more likely to be diagnosed with an earlier cancer stage and TNM status when compared with Medicaid or uninsured patients. Figure 3 showed that insured patients were more likely to receive definitive treatment when compared with Medicaid or uninsured patients. The chi-squared analysis data shown in Table 4 Figure 4 , demonstrated that the prognosis of the insured group was significantly better than that of the other two groups when using the raw data. After the adjustment of propensity score matching (PSM) (Supplementary Table 4 ), the effect of the insured group still existed with the balancing data as shown in Figure 4B . Following the Fine and Figure 5 , the patients were stratified by age group, race, and cancer site, which showed that insured patients always had the best TCSS outcomes.
Definitive treatment

Discussion
A retrospective cohort study used data from the Surveillance, Epidemiology, and End Results (SEER) database, and investigated the influence of insurance status on the disease stage at diagnosis, the definitive treatment, and the survival outcome in 54,232 patients with colorectal cancer (CRC). Among these patients, 86.2% were insured, 10.4% had Medicaid, and 3.3% were uninsured. Insurance status was a significant influencing factor of SEER stage. The SEER stage at diagnosis in Medicaid or uninsured patients was more advanced than insured patients. Insured patients had significantly earlier cancer stage and TNM status. As for definitive treatment, insurance status remained as a relevant factor, and insured patients were more likely to receive definitive treatment when compared with Medicaid or uninsured patients. Also, in terms of prognosis, the 5-year tumor cause-specific survival (TCSS) rates were 74.91% in the insured group, 63.46% in the Medicaid group, and 64.85% in the uninsured group. Both the Cox regression model and the Fine and Gray model showed that insurance status was an independent prognostic factor for TCSS. Insured patients had a better prognosis than either Medicaid or uninsured patients.
Socioeconomic factors, including household income, education level, and marital status, have previously been confirmed to affect tumor prognosis [13] [14] [15] [16] . CRC is the third most common cancer and the third leading cause of cancer death in the United States. However, the relationship between CRC and insurance status has not been previously studied in detail. In the present study, insurance status was found to be an independent predictive factor for disease stage, definitive treatment, and prognosis, which is consistent with the findings from previous studies in other cancers [6] . Tantraworasin et al. studied the effect of insurance type in Asian patients with lung cancer and found that uninsured or Medicaid Asian patients were more likely to be diagnosed with advanced disease, less likely to undergo treatment, and had shorter overall survival [17] . Similar results have been found for hepatocellular carcinoma and prostate cancer [5, 7] . In 2016, Rima et al. identified the association between race and insurance in patients with CRC, with similar findings to those of the present study, but only took into account limited patient demographic data, including only age, sex, race, marital status and insurance, probably due to problems with data acquisition [18] . The present study analyzed more variables, including income, education, residence or cancer site, to adjust for the complicated effects, and included stratified analysis to reduce bias, and adopted reasonable multinomial logistic models to detect the association between insurance and cancer stage [8] . However, in this stratified analysis, the effect of insurance status was not statistically significant in the subgroup aged more than 65 years. This finding may have been because the numbers of uninsured persons in those subgroups were less than 100, resulting in less adequate sample sizes [17] .
There are other potential reasons for the impact of insurance on the cancer stage at diagnosis. The results of this study showed that insured patients tended to be initially diagnosed at an early stage, probably because these patients were more likely to attend regular medical screening appointments and procedures, including colonoscopies or computed tomography (CT) colonography [4, 19, 20] . Therefore, CRC can be found at an earlier stage in insured patients [21] . CRC screening rates have increased between 2008 to 2015 in the United States, but the uninsured patient population continues to be screened for cancer at below the recommended levels [22] .
The disparities between treatment in Medicaid or uninsured patients compared with insured patients have been previously reported [23, 24] . In this study, the majority of patients with CRC received definitive treatment during the follow-up period, but the possibility of insured patients receiving treatment was significantly increased when compared with other patient groups. This finding may be because healthcare organizations preferentially admit, diagnose, and treat insured patients instead of Medicaid or uninsured patients [25] . Also, low income and weak social networks, which may be relevant factors of Medicaid or uninsured status, strongly hamper treatment [26] . Because of high treatment costs, uninsured patients may not seek treatment or screening for early diagnosis due to inability to pay the healthcare costs.
The differences in prognosis and patient survival among the patient groups with CRC and different insurance status were closely related to cancer stage and treatment. The data analyzed in this study demonstrated that uninsured or Medicaid patients were probably diagnosed at a more advanced stage, resulting in a worse survival outcome. Also, these patients tend to refuse definitive treatment, which also results in a poor prognosis. In this study, propensity score matching (PSM) was used to balance baseline variance among groups, and insured patients remained as having the optimal prognosis using KaplanMeier analysis. The traditional Kaplan-Meier analysis and Cox regression analysis often overestimate the risk of the tested event, which is overcome by the Fine and Gray proportional sub-distribution hazard analysis [27] . In this study, the Fine and Gray model was used to correct the hazard of predictive factors. Therefore, even if the effect of insurance status on prognosis was reduced by the Fine and Gray competing risk model, the results were still statistically significant.
Globally, human cancer results in a large medical and socioeconomic burden. The significance of the findings of this study indicates that medical insurance coverage should increase as part of healthcare reform to ensure that individuals have health insurance. Only in this way can the early diagnosis of cancer, including CRC, treatments, and prognosis be improved. In the USA, the government initiated Medicaid for partial uninsured individuals or minorities with low incomes and low education levels [28] . The original intention of Medicaid was to protect the insurance benefits of vulnerable groups and reduce the racial and socioeconomic imbalance in health care [7, 28] . However, according to the findings of this study, no significant difference was detected in TCSS between Medicaid and uninsured patients with CRC. The Medicaid patients had even more adverse survival outcomes than uninsured patients, after PSM. Therefore, whether it is a developed or developing country, expanding the coverage of medical insurance will be an important measure for government healthcare reform [26] . For CRC, private insurance for high-income individuals, and increasing the prevalence of Medicaid for low-income individuals, with the encouragement of screening programs using colonoscopy is recommended.
This study had several limitations. During the screening process of the SEER database, more than half of the original identified 100,000 patients were excluded, because of missing demographic, clinical and pathologic information, which might have resulted in selection bias. Some risk factors, including smoking status, alcohol use, medical comorbidities, and clinical complications, can affect the diagnosis, treatment and survival of patients with CRC. However, the SEER program did not collect these data for the target population. Also, the variables of household income and education level provided by the SEER database are not at patient-level, but at regional level. Detailed therapeutic regimens, including the use of specific chemotherapy, were not directly available from the SEER database, which was a limitation of the study, as chemotherapy has become a routine treatment for patients with advanced CRC. Insurance status, as the key variable, has been in the SEER database since 2007, but only consists of insured, Medicaid, and uninsured status. However, even insured status might be subdivided into private insurance, government Medicare, and coverage from the military or Veterans Affairs, which were inaccessible in the SEER database. The disparities among these different insurance states should be investigated in future studies. Also, given that this was a retrospective cohort study, based on the statistical methods, it was only possible to demonstrate correlations, instead of causality, between insurance status and cancer stage as well as definitive treatment. It is not possible to determine whether insured patients had an earlier cancer stage at diagnosis and inevitably received definitive treatment, and further studies are needed.
Conclusions
A large population-based analysis of patients with colorectal cancer (CRC) used data from the Surveillance, Epidemiology, and End Results (SEER) database. Insurance status was a significant factor that determined early diagnosis, definitive treatment, and was an independent factor for tumor causespecific survival (TCSS) in patients with CRC. Insured patients had a significantly earlier cancer stage at diagnosis, were significantly more likely to receive definitive treatment, and had a better prognosis than either patients with Medicaid or uninsured patients. In the USA, increased health insurance coverage may facilitate early diagnosis, promote definitive treatment, and improve the outcome for patients with CRC. 
